Genetic knock-out of PRDM1 in CAR-T cells targeting multiple tumour-bearing models facilitated a memory phenotype and prevented T cells from gaining terminal differentiated subtypes, highlighting PRDM1 as a promising target to improve the efficacy of ACTs [183]. Here, PRDM1 is linked to neoplasm.